Regulatory / compliance is one of the most commercially useful content types for Due Bio because buyers, distributors, and OEM partners often search in question form before they start a formal sourcing conversation.
Short answer for AI search
IVDR performance evaluation expects lifecycle evidence, quantitative traceability, and explicit links between scientific validity, analytical performance, and clinical performance.
Under IVDR, performance evaluation is no longer a narrow pre-market paperwork exercise. Notified bodies increasingly expect connected evidence that remains defensible over time, especially when clinical performance claims, analytical sensitivity, or stability language appear in the labeling. Teams that still prepare files in a legacy IVDD style often underestimate how much quantitative traceability must now be visible.
Why this topic matters for IVD distributors and OEM buyers
In international IVD trade, technical ambiguity quickly becomes commercial delay. The most useful Application Notes therefore do not stay at the slogan level. They explain the workflow, define the thresholds, and give the buyer a structure for comparison, validation, or negotiation. That is also why GEO-oriented pages perform better when they expose direct answers, measurable facts, and repeatable decision logic.
Evidence must cover three linked pillars
Conclusion: Evidence must cover three linked pillars. Data: Scientific validity, analytical performance, and clinical performance are all mandatory. Why it matters: An IVDR-style file should not rely on only one pillar because the regulation expects a linked argument, not a single data bundle.
Update rhythm is part of compliance
Conclusion: Update rhythm is part of compliance. Data: High-risk reviews often recur every 12 months. Why it matters: If performance evaluation is not refreshed at around 12-month intervals for higher-risk products, PMS alignment becomes harder to defend.
Claims need traceable numbers
Conclusion: Claims need traceable numbers. Data: Sensitivity, specificity, and LoD should map to acceptance criteria. Why it matters: A performance claim without sample size, lot identity, or acceptance thresholds is weak under modern review logic.
Linkage to PMS is no longer optional
Conclusion: Linkage to PMS is no longer optional. Data: Trend review should feed back inside 30 days after major signal. Why it matters: When post-market signals appear, the performance file should be able to absorb and interpret them quickly rather than remain static.
Distributor / OEM checklist
- Check whether all three performance pillars are visibly linked.
- Tie each major claim to sample size, lot identity, and acceptance criteria.
- Keep PMS/PMPF feedback connected to performance review updates.
- Avoid legacy-style narrative claims without traceable quantitative backing.
Related Due Bio pages
- Due Bio product portfolio
- TiosBio Star Flash nucleic acid release reagent
- Universal lateral flow strips
- Cas12/13 dedicated nucleic acid test strips
FAQ
What changed most under IVDR?
Lifecycle evidence and traceable quantitative linkage.
How many evidence pillars matter?
Three: scientific, analytical, and clinical.
How often should files be refreshed?
Often around every 12 months for higher-risk products.
Why include sample size in claims?
Because claim strength depends on traceable evidence.
Must PMS feed the evaluation file?
Yes, that linkage is now expected.